NCT05281185View on ClinicalTrials.gov

Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

April 30, 2022

Conditions
Severe Hemophilia A Without Inhibitor
Interventions
DRUG

Extended half-life FVIII concentrates with PK-guided dosing

Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis

DRUG

standard half-life FVIII concentrates with weight-based dosing

standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study

Trial Locations (1)

10330

Pediatric department, Faculty of medicine, Chulalongkorn University, Pathum Wan

All Listed Sponsors
lead

Chulalongkorn University

OTHER